drugset / Trial / NCT02192463
Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study to determine the relative bioavailability of different oral Viramune Extended Release (ER) formulations compared to Viramune® Immediate Release (IR) tablet
Timeline
- Start
- 2006-04
- Primary completion
- 2006-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nevirapine | Small molecule | 200 mg | Oral |
| Subject | Nevirapine | Small molecule | 300 mg | Oral |
| Subject | Nevirapine | Small molecule | 400 mg | Oral |
Indications
No indication recorded.